Tonghua Dongbao announcement, the company has completed the key phase I clinical trial of Degussen insulin Liraglutide injection and obtained the summary report. The results show that the main endpoint goal has been achieved. This drug is the world's first marketed composite preparation composed of basic insulin analogs and GLP-1 analogs, used for the treatment of type 2 diabetes. The main purpose is to evaluate its pharmacokinetic similarity to Novo Yi, with secondary objectives including evaluating its pharmacokinetic characteristics, safety, and tolerability. The trial results show that the drug produced by Tonghua Dongbao is bioequivalent to Novo Yi and well tolerated in healthy subjects, with good safety. The company's R&D investment in this project is approximately 41.2454 million yuan.